Ulcar (Sucralfate)

Quick links

Choose a section

Quick links to important sections

Advertisements

Ulcar (Sucralfate)

Advertisements

Overview of Ulcar (Sucralfate)

Property Description
Active Ingredient Sucralfate
Primary Forms Tablet, Oral Suspension
Pharmacological Class Anti-ulcer Agent, Protectant
General Purpose Provides localized mucosal protection
Origin Synthetic Organic Compound

What Type of Medicine is Ulcar (Sucralfate)?

Ulcar is a pharmaceutical product containing the single active ingredient Sucralfate, which is classified as an anti-ulcer agent and a cytoprotective protectant. This medication is a synthetic organic compound derived from sucrose and engineered to act exclusively through a localized mechanism within the gastrointestinal (GI) tract. Sucralfate is minimally absorbed and designed for non-systemic action, focusing its activity directly on the inner lining of the gut rather than affecting the entire body.

Sucralfate’s distinct classification differentiates it from acid-reducing drug families because its primary role is to provide a physical shield. It is supplied as a single-ingredient product intended for oral administration, typically used for patients requiring localized mucosal integrity support. The medication functions by creating a protective lining in the upper GI tract.

Composition and Available Forms of Sucralfate

The chemical basis for the drug is Sucralfate, which is an aluminum salt of sulfated sucrose, a structure designed to be reactive in the acidic environment of the stomach. This composition allows the compound to polymerize into a viscous, protective material upon contact with hydrochloric acid. The medication is widely available in two primary dosage forms: a standard tablet and an oral suspension (liquid).

What is the General Purpose of This Cytoprotectant?

The general purpose of Ulcar (Sucralfate) is to provide localized physical protection to areas of injury on the inner lining of the stomach and small intestine. By forming a stable, ulcer-adherent complex—essentially a protective bandage—the medication shields vulnerable tissue. This protective shield isolates the damaged mucosa from aggressive digestive factors, including acid, the enzyme pepsin, and bile salts, thereby creating an environment conducive to the body’s natural repair and healing processes.

Regulatory References

  1. WHO
  2. FDA's daily drug information
  3. DailyMed label
Advertisements

What side effects are possible with Ulcar (Sucralfate)?

Possible side effects and safety information

The safety profile of Sucralfate, based on regulatory classifications, shows that most reported adverse effects are non-serious and infrequent. The most commonly reported event in clinical trials is constipation, which occurs in approximately 2% of patients. Other reactions are generally reported in less than 0.5% of individuals.

Adverse reactions are classified by the body system affected, primarily involving the Gastrointestinal System (including dry mouth, flatulence, nausea, vomiting, indigestion, and gastric discomfort) and the Nervous System (including dizziness, headache, sleepiness, and vertigo).


Serious Adverse Reactions and Population Constraints

The official labeling documents several safety considerations that structure the risk profile, particularly for specific populations and uses:

  • Aluminum Accumulation and Toxicity: Patients with chronic renal failure or those receiving dialysis are at an increased risk of aluminum accumulation. This exposure, particularly with long-term treatment, can lead to serious conditions such as encephalopathy, osteodystrophy, and osteomalacia. Elderly patients are also considered more susceptible due to a higher likelihood of reduced renal function.
  • Bezoar Formation: There are reports of bezoar formation (a solid mass in the stomach) in patients, especially those with conditions that predispose them to impaired gastric emptying.
  • Administration Restriction: A critical safety constraint noted in the labeling is that the oral suspension is strictly for oral administration only. Fatal complications, including pulmonary and cerebral emboli, have been reported following the inappropriate intravenous administration of the product. Sucralfate’s localized action may also alter the absorption of certain other orally administered medications.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ulcar (Sucralfate) overdose is defined by the drug's limited systemic absorption.

Overdose Scope

  • Documented overdose presentations: Acute oral overdosage is frequently reported as asymptomatic. In rare reports, adverse events included mild gastrointestinal symptoms such as dyspepsia, abdominal pain, nausea, and vomiting.
  • Physiological systems affected: The gastrointestinal system is noted in manifestation reports. The renal and central nervous systems (CNS) are implicated in the context of chronic aluminum accumulation and resultant toxicity.
  • Dose-related or exposure-related factors: The risk associated with acute oral overdosage is deemed minimal by regulators due to the drug’s minimal absorption from the gastrointestinal tract.
  • Population-specific overdose notes: The risk of toxic reactions is greater in patients with impaired renal function, including those undergoing dialysis, due to the potential for aluminum accumulation and toxicity.
  • Emergency-response statements: Seek emergency medical attention or call the Poison Help line if an overdose is suspected. No specific treatment recommendations can be given for acute oral overdosage.
  • When immediate medical help is required: Call emergency services immediately if symptoms include collapse, a seizure, trouble breathing, or inability to be awakened.

Overdose Classifications (High-Level)

  • Severity classification: Acute oral overdosage is classified as minimal risk.
  • Regulatory basis: Information is based on official documents, including FDA Prescribing Information and NIH MedlinePlus.
  • Overdose-context constraints: Management is symptomatic and supportive, consistent with the statement that no specific treatment is known.

Resulting overdose structure

  • Official overdose statements:
    • Acute oral overdosage of Sucralfate is associated with minimal risk.
    • No specific treatment recommendations are available for acute oral overdosage.
    • Emergency medical attention is mandated when severe clinical signs such as collapse or seizure are present.
    • The drug's aluminum content presents a risk of aluminum accumulation in patients with impaired renal function.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile as primarily low-risk in the acute setting, with presentations often being asymptomatic or involving mild gastrointestinal symptoms. However, regulators mandate that emergency medical attention must be sought immediately for any severe symptoms, such as collapse or seizure. This profile explicitly flags a critical, population-specific risk of aluminum accumulation and potential toxicity when renal clearance is impaired.

Advertisements

Therapeutic Uses of Ulcar (Sucralfate)

What Ulcar (Sucralfate) Treats: Main Uses and Benefits

Ulcar (Sucralfate) is commonly used to help manage symptoms and promote healing in conditions involving significant mucosal injury in the upper GI tract. The medication is relevant in clinical settings marked by heightened symptomatic discomfort associated with active lesions, which includes duodenal ulcers, gastric ulcers, and various inflammatory conditions like gastritis and esophagitis. It is applied when symptoms cluster into patterns of pronounced pain and irritation due to tissue damage.

“This supportive use provides support that helps ease the overall symptom burden during difficult acute episodes.”

For patients prone to recurrence, the medication is relevant in situations requiring long-term assistance in symptom stabilization following the successful healing of duodenal ulcers. By offering supportive therapeutic benefit, it is relevant for managing symptoms that may recur, which may contribute to improved day-to-day comfort by avoiding the return of disruptive ulcer manifestations. It is also applicable in specialized scenarios, such as managing painful mucositis or radiation proctitis, providing supportive relief when symptoms interfere with routine activities stemming from local irritative states.


Quick Fact: Relief for Pain and Irritation

This medication plays a role in managing symptoms primarily when symptoms are related to inflammatory or irritative states. This use contributes to easing the overall symptom load during symptomatic periods associated with active tissue injury.

Regulatory References

  1. NIH DailyMed drug label
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Ulcar (Sucralfate)?

Official regulatory documents define specific eligibility and non-eligibility for sucralfate use. The primary contraindication is a known hypersensitivity reaction to the active substance or any of the drug’s excipients.

Restricted and Cautionary Use

Use requires special caution and monitoring in several populations:

  • Chronic Renal Impairment/Dialysis: Patients with chronic renal failure or those on dialysis have impaired excretion of absorbed aluminum. Sucralfate contains aluminum, and its use in this population may lead to accumulation and aluminum toxicity.
  • Conditions Predisposing to Bezoar Formation: Caution is advised for individuals with conditions like delayed gastric emptying or those receiving enteral tube feedings, as this may increase the risk of forming a solid mass (bezoar) in the stomach.
  • Pediatric Patients: The safety and effectiveness of sucralfate have not been established in the pediatric population.
  • Pregnancy: Use during pregnancy is only recommended if clearly needed, as human studies are inadequate. Caution is also advised when administering to a nursing woman.
  • Elderly: Use with caution due to the greater likelihood of decreased renal function; monitoring of kidney function may be warranted.
Advertisements

What should I know about interactions with other medicines?

The official interaction profile of Sucralfate is defined by its localized action, resulting in two main types of documented interactions. The primary pattern is nonsystemic binding in the gastrointestinal tract, which can reduce the extent of absorption (bioavailability) of other orally administered medications. This effect has been documented for numerous substances, including cimetidine, digoxin, levothyroxine, phenytoin, quinidine, ranitidine, theophylline, and various fluoroquinolone antibiotics.

To manage this reduction in exposure, regulatory labeling specifies mandatory separation rules. Critical oral medications must be administered two hours before Sucralfate. Co-administration with antacids must be separated by at least 30 minutes, and the suspension must be separated from enteral feeds by one hour.

The second interaction concern is related to the aluminum component. Co-administration with citrate preparations is formally restricted because it may increase the systemic absorption of aluminum, raising the risk of aluminum accumulation and toxicity. This risk is specifically noted as greater in patients with chronic renal failure or those undergoing dialysis, due to impaired excretion of absorbed aluminum. This interaction information is derived exclusively from major government regulatory documents.

Advertisements

Mechanism of Action

How Ulcar (Sucralfate) Works: Mechanism of Action

Sucralfate exerts a non-systemic, localized effect primarily through physicochemical mechanisms at the site of mucosal injury. This action initiates with acid-dependent polymerization: upon exposure to gastric hydrochloric acid ( pH<4), the sulfated sucrose molecule transforms into a dense, viscous anionic polymer.

This polymer exhibits selective adherence, binding strongly to the positively charged protein exudates found on the surface of damaged mucosal tissue, forming an impervious physical barrier or plaque. This barrier then acts via adsorption to sequester proteolytic agents like pepsin and bile salts, minimizing the ongoing chemical and enzymatic degradation of tissue. This reduction in chemical assault creates a physiological micro-environment allowing cellular processes to commence tissue repair.

A secondary mechanism involves the local modulation of cytoprotection pathways. Sucralfate stimulates the synthesis and release of prostaglandins (PGE2/PGI2) by adjacent mucosal cells. This cascade increases bicarbonate and mucus secretion and improves local microcirculation, reinforcing the structural integrity of the surrounding mucosa.

Advertisements

Dosage and Administration Information

How to Use Ulcar (Sucralfate)

Sucralfate, the active component in Ulcar, is an anti-ulcer agent administered exclusively via the oral route. It is supplied in two primary forms: a 1 gram tablet and an oral suspension of 1 g per 10 mL. The instructions for its use are defined by administration timing and duration, ensuring localized action on the gastrointestinal lining.


Dosing and Frequency Patterns

The standard approach to sucralfate use distinguishes between acute treatment and long-term supportive regimens.

Regimen Dose Frequency Typical Duration
Active Duodenal Ulcer 1 gram Four times per day (QID) 4 to 8 weeks (or until healing is confirmed)
Maintenance Therapy 1 gram Twice a day (BID) Generally extended, often up to 1 year in controlled studies

Administration Conditions and Constraints

The effective use of sucralfate is highly dependent on specific administration conditions to maximize its localized protective capability. The medicine must be taken on an empty stomach. To prevent interference with the formation of the protective barrier, antacids must be taken at least one-half hour before or after sucralfate administration. Likewise, when altered absorption is critical, many other medications should be scheduled 2 hours before sucralfate.

Special Administrative Rules: The oral suspension requires thorough shaking before each use. Intravenous administration is forbidden under all circumstances. For specific populations, such as older adults, dose selection should be cautious, typically starting at the lower end of the dosing range.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ulcar (Sucralfate)


Duodenal and Gastric Ulcer Healing: The Primary Evidence Base

The research base for Sucralfate involves Randomized Controlled Trials (RCTs), where studies explored outcomes related to physical discomfort in populations characterized by duodenal ulcers and gastric ulcers. These are short-term studies, often lasting between four and twelve weeks, conducted on adult patients with ulcers confirmed by endoscopy. Researchers primarily monitored the Endoscopic Healing Rate—a technical measurement of whether the ulcer completely disappeared during the study period.

Research so far indicates that studies reported patterns related to endoscopic measurements over the short-term use period. These initial studies were frequently designed to compare Sucralfate against a placebo (an inactive treatment) or against older anti-ulcer medications. Findings describe patterns observed in the studies related to endoscopic endpoints and changes measured during the study period.

Long-Term Evidence: Preventing Ulcer Recurrence

Following the healing of a duodenal ulcer, research was studied for maintenance use to prevent the ulcer from recurring. These maintenance randomized trials typically studied adults who had achieved initial healing and monitored them over intermediate-term follow-up durations, generally spanning six months to one year.

In these studies, research examined outcomes related to Time to Ulcer Recurrence and the frequency of patients experiencing the return of outcomes linked to inflammatory or irritative states. Findings describe patterns observed in the studies related to the stability of endoscopic endpoints over the course of the monitoring period.

Evidence for Use in Specialized Mucosal Protection

Research also was evaluated in more specialized clinical scenarios where local mucosal protection may be relevant. This includes trials aggregated by Systematic Reviews and Meta-Analyses concerning its use for stress ulcer prevention in adult critically ill patients. Furthermore, smaller trials and observational studies was evaluated in various conditions involving outcomes linked to inflammatory or irritative states. These studies measured outcomes related to patient-reported outcomes describing perceived discomfort.

What Remains Uncertain in the Sucralfate Research

Despite the established base of RCTs, research highlights several areas where certainty remains low or data are still emerging. A key limitation is that comparative evidence against contemporary standard treatments such as Proton Pump Inhibitors (PPIs) is limited in the established literature. Additionally, the follow-up durations were limited in many key trials, meaning long-term effects are not fully established. Studies help show what has been observed so far and highlights what is known—and what is still uncertain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ulcar (Sucralfate) (FAQ)


Q: How soon after taking Ulcar (Sucralfate) can I eat or drink something else?

Regulatory guidance states that sucralfate should be taken on an empty stomach for maximum effectiveness. Official information advises taking this medication at least 1 hour before or 2 hours after meals. This time separation helps the drug to form its protective coating in the gastrointestinal tract.

Q: How effective is Ulcar (Sucralfate) compared to just waiting for an ulcer to heal naturally?

Studies cited in the official product information found that Sucralfate was superior to placebo (an inactive treatment) for healing duodenal ulcers. This finding indicates that sucralfate helps to promote ulcer healing compared to no active treatment.

Q: Why do some people need to take Ulcar (Sucralfate) multiple times a day?

Sucralfate is a non-systemic drug, meaning it works only locally at the site of the ulcer and is minimally absorbed. Because its protective action is localized, it is generally prescribed for multiple daily administrations to maintain its continuous protective action over the damaged area.


Q: Can I take pain relievers like ibuprofen while using Ulcar (Sucralfate)?

Sucralfate has the potential to reduce the absorption of many other oral medications. Regulatory labeling specifies that oral pain relievers, like many other oral medications, must be separated from sucralfate administration by at least 2 hours to minimize potential interaction.

Q: Is Ulcar (Sucralfate) known to interact with thyroid medications?

Yes, regulatory documents indicate that Sucralfate may reduce the absorption of certain oral thyroid hormones (such as levothyroxine) due to its localized binding action in the gut. Official guidance recommends that these thyroid medications be administered at least 2 hours before sucralfate.

Q: Can Ulcar (Sucralfate) cause an allergic reaction?

Yes, allergic reactions (hypersensitivity) can occur with Sucralfate use, although they are rare. This possibility is noted in the official product labeling. Symptoms of a severe reaction may include rash, hives, itching, and swelling of the face, tongue, or throat.

Q: What should I do if I experience a potential side effect from Ulcar (Sucralfate)?

For common or non-serious side effects, official guidance suggests contacting a healthcare provider. Signs of a severe reaction (such as swelling or difficulty breathing) are considered a medical emergency and require immediate attention.


Q: Are there any dietary restrictions recommended while taking Sucralfate?

Unless otherwise instructed by a healthcare provider, a person should continue their normal diet. The main dietary consideration is ensuring the medication is taken on an empty stomach and separated from meals.

Q: Is Ulcar (Sucralfate) commonly used to prevent ulcers?

Yes, Sucralfate is officially indicated for use as maintenance therapy to prevent the recurrence of duodenal ulcers after initial healing has occurred. This preventative regimen is typically given at a lower dose than the active treatment dose.

Q: What is the maximum long-term duration for maintenance therapy?

Maintenance therapy, which aims to prevent ulcers from returning, has been studied in controlled clinical trials for durations of up to 1 year.

Q: Why is Ulcar (Sucralfate) sometimes prescribed for problems not directly related to ulcers?

Sucralfate's primary function is to provide a protective, localized coating to damaged tissue (mucosa). This cytoprotective action has led to its use in other conditions where the lining of the digestive tract is irritated, such as gastritis and reflux disease.

Advertisements

How should Ulcar (Sucralfate) be stored and disposed of?

How to Store and Dispose of Ulcar (Sucralfate)?

Official regulatory documents mandate strict conditions for storing sucralfate, including both tablet and oral suspension forms.


Storage Requirements

Sucralfate must be stored at Controlled Room Temperature, which is defined as 20^circ to 25 C (68^circ to 77 F). Storage must be away from excess heat and moisture.

  • The Oral Suspension must not freeze.
  • The medication must remain in its original container and be kept tightly closed.

Child Safety and Disposal

As a safety measure, sucralfate must be kept out of the sight and reach of children.

Unused or expired sucralfate should be disposed of by following the directions provided by a pharmacist or local waste disposal company. Do not dispose of the medication by flushing it down a toilet or pouring it down a sink unless specifically instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcar (Sucralfate) found in:

A-Z Index: